Literature DB >> 19137294

Cerebral perfusion (HMPAO-SPECT) in patients with depression with cognitive impairment versus those with mild cognitive impairment and dementia of Alzheimer's type: a semiquantitative and automated evaluation.

W Staffen1, J Bergmann, U Schönauer, H Zauner, M Kronbichler, S Golaszewski, G Ladurner.   

Abstract

PURPOSE: Comparative evaluation of regional brain perfusion measured by HMPAO-SPECT of patients with mild cognitive impairment (MCI), dementia of Alzheimer's type (DAT) and depression with cognitive impairment (DCI).
METHODS: A total of 736 patients were investigated because of suspected cognitive dysfunction. After exclusion of patients with other forms of dementia than DAT or relevant accompanying disorders, SPECT data from 149 MCI, 131 DAT and 127 DCI patients, and 123 controls without any cognitive impairment, were analysed. Relative cerebral blood flow of 34 anatomical regions was assessed with automated analysis software (BRASS).
RESULTS: Calculation of global forebrain perfusion discriminated demented from nondemented patients. Compared to controls DCI patients showed hypoperfusion of the thalamus, lentiform nucleus and medial temporal cortex. MCI patients differed significantly from controls concerning perfusion in both hemispheric temporal and parietal areas, and in the (right hemispheric) posterior part of the cingulate gyrus. MCI and DCI patients differed in the parietal, temporal superior and right hemispheric cingulate gyrus posterior cortices. Global forebrain and regional perfusion was more extensively reduced in DAT patients and discriminated them from controls, and MCI and DCI patients. Frontal perfusion disturbance was only present in DAT patients.
CONCLUSION: Automated analysis of HMPAO-SPECT data from MCI patients showed significant perfusion deficits in regions also involved in DAT patients, but ROC analysis demonstrated only moderate sensitivity and specificity for differentiating DAT patients from controls and DCI patients. Frontal hypoperfusion seems to correspond with conversion from MCI to DAT. Finally, the results in DCI patients again raise the question of depression as an early symptom of neurodegeneration.

Entities:  

Mesh:

Year:  2009        PMID: 19137294     DOI: 10.1007/s00259-008-1028-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  58 in total

1.  Decreased cerebral blood flow and prognosis of Alzheimer's disease: a multicenter HMPAO-SPECT study.

Authors:  Tsunehiko Nishimura; Kazuo Hashikawa; Hidenao Fukuyama; Takao Kubota; Shin Kitamura; Hiroshi Matsuda; Haruo Hanyu; Hidehiko Nabatame; Naohiko Oku; Hirotaka Tanabe; Yasuo Kuwabara; Seishi Jinnouchi; Atsushi Kubol
Journal:  Ann Nucl Med       Date:  2007-01       Impact factor: 2.668

2.  FDG PET imaging in patients with pathologically verified dementia.

Authors:  J M Hoffman; K A Welsh-Bohmer; M Hanson; B Crain; C Hulette; N Earl; R E Coleman
Journal:  J Nucl Med       Date:  2000-11       Impact factor: 10.057

3.  Structural neuroimaging in the diagnosis of dementia.

Authors:  Tiffany Chow
Journal:  Alzheimers Dement       Date:  2007-09-10       Impact factor: 21.566

4.  Brain single photon emission computed tomography findings in depressive pseudodementia patients.

Authors:  Maeng Je Cho; In Kyoon Lyoo; Dong Woo Lee; Jun Soo Kwon; Jae Sung Lee; Dong Soo Lee; June Key Jung; Myung Chul Lee
Journal:  J Affect Disord       Date:  2002-05       Impact factor: 4.839

5.  Evaluation of brain perfusion SPECT using an easy Z-score imaging system (eZIS) as an adjunct to early-diagnosis of neurodegenerative diseases.

Authors:  Masaaki Waragai; Tatsuo Yamada; Hiroshi Matsuda
Journal:  J Neurol Sci       Date:  2007-05-09       Impact factor: 3.181

6.  Predictors of progression from mild cognitive impairment to Alzheimer disease.

Authors:  K Palmer; A K Berger; R Monastero; B Winblad; L Bäckman; L Fratiglioni
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

Review 7.  The role of neuroimaging in mild cognitive impairment.

Authors:  Hiroshi Matsuda
Journal:  Neuropathology       Date:  2007-12       Impact factor: 1.906

Review 8.  Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Authors:  Harald Hampel; Katharina Bürger; Stefan J Teipel; Arun L W Bokde; Henrik Zetterberg; Kaj Blennow
Journal:  Alzheimers Dement       Date:  2007-12-21       Impact factor: 21.566

9.  Role of neuroimaging in Alzheimer's disease, with emphasis on brain perfusion SPECT.

Authors:  Hiroshi Matsuda
Journal:  J Nucl Med       Date:  2007-07-13       Impact factor: 10.057

10.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Yi Li; Juha O Rinne; Lisa Mosconi; Elizabeth Pirraglia; Henry Rusinek; Susan DeSanti; Nina Kemppainen; Kjell Någren; Byeong-Chae Kim; Wai Tsui; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

View more
  15 in total

1.  The APOE ɛ4/ɛ4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients.

Authors:  Karin Hultman; Sidney Strickland; Erin H Norris
Journal:  J Cereb Blood Flow Metab       Date:  2013-05-08       Impact factor: 6.200

2.  Initial mini-mental state and cerebral perfusion in Alzheimer's disease.

Authors:  T Ones; I Midi; F Dede; N Tuncer; T Y Erdil; O Onultan; S Ceylan; S Inanir; H T Turoglu
Journal:  Clin Neuroradiol       Date:  2012-01-03       Impact factor: 3.649

3.  Plasmin deficiency leads to fibrin accumulation and a compromised inflammatory response in the mouse brain.

Authors:  K Hultman; M Cortes-Canteli; A Bounoutas; A T Richards; S Strickland; E H Norris
Journal:  J Thromb Haemost       Date:  2014-05       Impact factor: 5.824

4.  Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease.

Authors:  Marta Cortes-Canteli; Justin Paul; Erin H Norris; Robert Bronstein; Hyung Jin Ahn; Daria Zamolodchikov; Shivaprasad Bhuvanendran; Katherine M Fenz; Sidney Strickland
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

5.  Voxel-based morphometry findings in Alzheimer's disease: neuropsychiatric symptoms and disability correlations - preliminary results.

Authors:  Luciano de Gois Vasconcelos; Andrea Parolin Jackowski; Maira Okada de Oliveira; Yoná Mayara Ribeiro Flor; Orlando Francisco Amodeo Bueno; Sonia Maria Dozzi Brucki
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

6.  Expression of Tau protein in rats with cognitive dysfunction induced by cerebral hypoperfusion.

Authors:  Ji-Feng Li; Zhou Wang; Qin-Jian Sun; Yi-Feng Du
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 7.  Fibrinogen and altered hemostasis in Alzheimer's disease.

Authors:  Marta Cortes-Canteli; Daria Zamolodchikov; Hyung Jin Ahn; Sidney Strickland; Erin H Norris
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

8.  Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

Authors:  Jean-Paul Soucy; Robert Bartha; Christian Bocti; Michael Borrie; Amer M Burhan; Robert Laforce; Pedro Rosa-Neto
Journal:  Alzheimers Res Ther       Date:  2013-07-08       Impact factor: 6.982

9.  Behavioral and psychological symptoms of dementia.

Authors:  J Cerejeira; L Lagarto; E B Mukaetova-Ladinska
Journal:  Front Neurol       Date:  2012-05-07       Impact factor: 4.003

10.  Blood platelets in the progression of Alzheimer's disease.

Authors:  Nina S Gowert; Lili Donner; Madhumita Chatterjee; Yvonne S Eisele; Seyda T Towhid; Patrick Münzer; Britta Walker; Isabella Ogorek; Oliver Borst; Maria Grandoch; Martin Schaller; Jens W Fischer; Meinrad Gawaz; Sascha Weggen; Florian Lang; Mathias Jucker; Margitta Elvers
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.